World Class. Our People. Our Science. Our Therapies. Press Releases ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More Impact of RSV highlighted on BBC Radio 4’s ‘Inside Health’ Programme Feb 4, 2020 by ReViral Ltd Read More ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy Jan 27, 2020 by ReViral Ltd Read More ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors Nov 27, 2019 by ReViral Ltd Read More Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection Nov 18, 2019 by ReViral Ltd Read More Archives Archives Select Year 2020 2019 2018 2017 2016 2015 2014 2013 View All
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More
Impact of RSV highlighted on BBC Radio 4’s ‘Inside Health’ Programme Feb 4, 2020 by ReViral Ltd Read More
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy Jan 27, 2020 by ReViral Ltd Read More
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors Nov 27, 2019 by ReViral Ltd Read More
Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection Nov 18, 2019 by ReViral Ltd Read More
